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ABSTRACT 
 
      The brainstem is a structurally complex region, containing numerous ascending 
and descending fibres that converge on centres that regulate bodily functions essential 
to life. Afferent input from the cranial tissues and the special senses is processed, in 
part, in brainstem nuclei. In addition, brainstem centres modulate the flow of pain 
messages and other forms of sensory information to higher regions of the brain, and 
influence the general excitability of these cortical regions.  Thus, disruptions in 
brainstem processing might  evoke a complex range of unpleasant symptoms, 
vegetative changes and neurovascular disturbances and that, together, form attacks of 
migraine. Migraine is linked with various co-morbid conditions, the most prominent 
being motion sickness.  Symptoms such as nausea, dizziness and headache are 
common to motion sickness and migraine; moreover, migraine sufferers have a 
heightened vulnerability to motion sickness. As both maladies involve reflexes that 
relay in the brainstem, symptoms may share the same neural circuitry.  In 
consequence, subclinical interictal persistence of disturbances in these brainstem 
pathways could not only increase vulnerability to recurrent attacks of migraine but 
also increase susceptibility to motion sickness. Mechanisms that mediate symptoms of 
motion sickness and migraine are explored in this paper. The physiology of motion 
sickness and migraine is discussed, and neurotransmitters that may be involved in the 
manifestation of symptoms are reviewed. Recent findings have shed light on the 
relationship between migraine and motion sickness, and provide insights into the 
generation of migraine attacks.    
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1.  Introduction 
The brainstem is structurally and functionally complex, comprising numerous 
ascending and descending neural pathways and nuclei that regulate functions essential 
to life (Standring, 2004). Afferent input from the cranial tissues and the special senses 
is processed, in part, in the brainstem, and brainstem pain modulation centres modify 
nociceptive sensations before they arrive at their subcortical and cortical destinations. 
Thus, it is not surprising that recent theories of migraine have focused on the 
brainstem as a source of the neurovascular disturbances and symptoms that 
accompany attacks (Lance and Goadsby, 2005; Lambert and Zagami, 2009).  
Various co-morbid conditions, which necessarily involve brainstem circuitry, 
have been linked with migraine such as sleep apnoea (Proceta and Dalessio, 1995), 
asthma (Medina and Diamond, 1976) and stroke (Lidegaard, 1995), but the closest fit 
in terms of symptoms would appear to be motion sickness.   These symptoms arise 
due to a mismatch between visual, proprioceptive or vestibular cues of motion, 
possibly to warn the body of a potential threat to homeostasis.  The conflicting central 
sensory input evokes physiological disturbances that resemble effects of poisoning, 
and results in pre-emptive nausea and vomiting (Triesman, 1977; Money, 1990). 
Numerous structures, pathways and mechanisms are implicated in the complex 
neurophysiology of motion sickness (Crampton, 1990; Harm, 1990; Yates, Miller and 
Lucot, 1998), but the brainstem appears to play a pivotal coordinating role.  
The essential mediator for movement-induced motion sickness is the 
vestibular apparatus (Yates et al., 1998), as animals and humans with no functional 
vestibular apparatus do not develop motion sickness during rotation or when placed in 
low-gravity environments associated with the exploration of space (Crampton, 1990; 
Igarashi, 1990; Money, 1990). Visually-induced motion sickness does not involve   6 
direct vestibular stimulation but, nevertheless, involves converging sensory inputs 
(vestibular, visual, somatosensory) that are at variance with sensory integration from 
the ‘neural store’ (memory, past experience) (Takedo,  Morita, Horii, Nishiike, 
Kitahara and Uno, 2001).  This neural mismatch results in motion sickness.    
       As headache, nausea, dizziness, drowsiness and perceived changes in body 
temperature  are common to migraine and motion sickness (Marcus, Furman and 
Baleban, 2005), the same neural pathways may be active in both conditions.   The 
manifestation of these symptoms involves reflexes that relay in the brainstem, 
possibly in nuclei that become active during migrainous attacks (Weiller, May, 
Limmroth, Jǔptner, Kaube, Schayck and Diener, 1995).  Subclinical excitability in 
these brainstem reflexes could increase vulnerability to repeated attacks of migraine, 
and could increase susceptibility to motion sickness.  Aspects of motion sickness 
related to migraine, and the implications of this relationship, are discussed below.   
2.  Mechanisms of migraine 
       Migraine is a complex neurological disorder characterized by headache and 
associated symptoms,  including nausea and vestibular disturbances (Headache 
Classification Subcommittee of the International Headache Society, 2004).   Brain 
imaging studies have recently provided new insights into the mechanism of attacks. 
However, the neural events that increase susceptibility to migraine and that link 
trigger factors, such as stress and hormonal changes, with the initiation of attacks, are 
still poorly understood (Bolay, Reuter, Dunn, Huang, Boas and Moskowitz, 2002; 
Williamson and Hargreaves, 2001; Lambert and Zagami, 2009).    
2.1.  Brainstem and hypothalamic involvement 
         Symptoms of brainstem and hypothalamic disturbance often precede migraine, 
and focal brainstem activity develops during attacks (Weiller et al., 1995).  Positron   7 
emission tomography (PET) indicates that activity in certain brainstem and midbrain 
nuclei (e.g., nucleus raphe dorsalis, nucleus raphe magnus, locus coeruleus and 
periaqueductal grey matter) increases in spontaneous attacks of migraine (Weiller et 
al., 1995; Bahra, Matharu, Buchel, Frackowiak and Goadsby, 2001; Diener, 1997, 
1999).  Consistent with these findings, Raskin, Hosobuchi and Lamb (1987) observed 
migraine-like headache in 15 of 175 patients following implantation of electrodes into 
the midbrain periaqueductal grey or somatosensory region of the thalamus for 
treatment of intractable pain.  In contrast to migraine, attacks of cluster headache and 
other trigeminal autonomic headaches are associated with hypothalamic rather than 
brainstem activation (May, Bahra, Büchel, Frackowiak and Goadsby, 1998; Bahra et 
al., 2001; May, 2003; May, 2009). However, this dissociation may not be clearcut, as 
Denuelle, Fabre, Payoux, Chollet and Geraud (2007) recently recorded increased 
activity in the hypothalamus in addition to the pons using H2
15O-PET in seven patients 
during spontaneous attacks of migraine without aura.  Activity persisted in these 
regions after headache was relieved following treatment with sumatriptan. Denuelle et 
al. proposed that the persistence of hypothalamic activity after headache relief might 
indicate the activation of a nociceptive generator or an antinociceptive mechanism in 
the hypothalamus. In particular, the persistence of hypothalamic activity after 
sumatriptan had relieved the pain might implicate this  part of the brain in the 
generation of migraine attacks, as this would explain the frequent recurrence of 
headache following treatment with sumatriptan (Weiller et al., 1995).    
         Increased activity on high resolution PET was also observed in the left dorsal 
pons, in the thalamus contralateral to pain, and in the right anterior cingulate, 
posterior cingulate, cerebellum, insula, prefrontal cortex, and temporal lobes during 
spontaneous migraine headache (Afridi et. al., 2005a). In a related study, Afridi et al.   8 
(2005b) administered glyceryl trinitrate (GTN) intravenously to 24 migraine sufferers 
and 8 healthy controls.  All migraine sufferers experienced mild headache during the 
GTN infusion, which eventually developed into typical migraine headache. H2
15O-PET 
revealed brainstem activation in the dorsal lateral pons during the migraine attack. 
Activation was ipsilateral to the side of headache in the right- and left-sided groups, 
and bilateral with a left-sided tendency in the bilateral group. Based on these findings, 
Afridi et al. proposed that the lateralization of pain in migraine may reflect lateralized 
brain dysfunction. 
        In general, such findings have led to the concept that the midbrain and brainstem 
is the migraine “generator”.    Specifically, it was proposed that an abnormality might 
lead to an imbalance in brainstem regulation of cerebral blood vessels and pain in 
migraine sufferers (Weiller et al., 1995).   Consistent with this notion, PET revealed 
activation of cerebral structures corresponding to the rostral brainstem and intra- and 
extracranial blood vessels during an attack of migraine without aura following 
administration of 1.2g GTN in a man with a history of migraine and cluster headache 
(Bahra et al., 2001).   Bahra and colleagues proposed that vasodilatation may be 
neurally-driven from brainstem activation (there was no apparent activation in the 
hypothalamus).  As noted above, however, the hypothalamus might also be involved 
in the generation of migraine (Denuelle et al., 2007), perhaps via activation of 
hypothalamic nuclei and their connections with those in the brainstem (Lance, 1989).      
2.2.  The trigeminovascular system in migraine 
        As the brain itself is largely insensitive to pain, intracranial pain is probably 
generated from intracranial blood vessels (Lance and Goadsby, 2005).   These vessels 
are supplied with sympathetic, parasympathetic and sensory nerve fibres (Edvinsson 
and Uddman, 2005).  Intense activation of trigeminal pain pathways in cluster   9 
headache and migraine may initiate parasympathetic reflexes in the superior 
salivatory nucleus, resulting in the release of the vasodilator vasoactive intestinal 
polypeptide and the manifestation of facial symptoms such as ipsilateral flushing and 
lacrimation (Edvinsson and Uddman, 2005; Knight, 2005). In the extreme, the 
intracranial vasodilatation evoked by these reflexes may compress sympathetic 
vasoconstrictor fibres that travel with the internal carotid artery through the carotid 
canal, ultimately releasing sympathetic vasoconstrictor tone and aggravating 
vasodilatation. In such instances, compression of perivascular trigeminal nociceptive 
fibres in the carotid canal could act as a secondary source of pain. 
        The trigeminal nerve contains sensory and motor components but the sensory 
component, in particular, appears to be associated with migraine pathophysiology 
(Williamson and Hargreaves, 2001; Borsook, Burstein, Moulton and Becerra, 2006).  
The trigeminal nerve, the fifth and largest of the cranial nerves, has three divisions: 
the ophthalmic, maxillary and mandibular.  The sensory fibres of all three divisions 
enter the brainstem and project to nuclei in the pons or medulla, or enter the spinal 
trigeminal tract.  Sensory information from the face and forehead, including pain, 
thermal and tactile sensations, are conveyed to higher brain centres via this nerve. 
         Branches of the trigeminal nerve also innervate cerebral blood vessels and the 
dura mater.  Specifically, a collection of cell bodies in the trigeminal ganglion 
regulates blood flow in the pain-sensitive large cranial vessels and dura mater 
(O’Conner and van der Kooy, 1986; May and Goadsby, 1999), the pia mater 
(Mayberg, Langer, Zervas and Moskowitz, 1981), forebrain and the rostral basilar 
artery (Arbab, Wiklund and Svendgaard, 1986).  Nerve fibres that project from the 
peripheral and central arms of the trigeminovascular system provide pathways for the 
transmission of pain signals from cranial vessels to brain centres involved in pain   10 
sensation  (Borsook et al., 2006), thereby providing the framework for trigeminal 
nociceptive activity to dilate cranial vessels. This may operate by two means: a 
trigeminal-parasympathetic reflex that dilates extracranial blood vessels; and a 
neurogenic inflammatory process that involves release of neuropeptides such as 
calcitonin gene-related peptide (CGRP) from trigeminal nerve terminals (Lambert, 
Bogduk, Goadsby, Duckworth and Lance, 1984; Goadsby, Lambert and Lance, 1986). 
An interaction between trigeminal-parasympathetic vasodilatation and neurogenic 
inflammation could then establish a vicious circle, driven by trigeminal nociceptive 
discharge. What initially triggers the trigeminovascular reflex in migraine is unclear 
but one possibility could be the release of inflammatory mediators within the brain 
parenchyma or supporting tissues.  After the provoking stimulus is removed, 
sensitization of trigeminal nerve fibres evoked by the inflammatory response may 
cause pain to persist (Macfarlane, 1993).   
         Neuropeptides released during neurogenic inflammation activate mast cells, 
vascular endothelial cells and platelets, resulting in the further release of extracellular 
inflammatory mediators.  This chemical cascade of activated cells and inflamed tissue 
may lead to hyperalgesia and pain (Moskowitz, 1993; Silberstein, 2003). Neurogenic 
inflammation could also contribute to the scalp tenderness associated with migraine 
headache.  Tenderness to mechanical stimulation of the scalp persists for up to a week 
after episodes of migraine (Drummond, 1987), implying that pain mechanisms such as 
neurogenic inflammation and central sensitization outlast the headache itself and may 
act as a latent source of pain during the headache-free period. 
        Neurogenic inflammation is characterized by two distinct processes – plasma 
protein extravasation (PPE) and neurogenic vasodilatation.  Peroutka (2005) evaluated 
data from animal models of neurogenic inflammation in relation to the human   11 
condition.   PPE is mediated by tachykinins  (e.g., substance P) and endothelin-3 
whereas neurogenic vasodilatation is mediated primarily by CGRP.  Peroutka noted 
that inhibitors of PPE identified in animal studies were ineffective in the acute 
treatment of migraine.  However, CGRP antagonists have met with greater success 
(Ho et al., 2008; Olesen et al., 2004), suggesting that neurogenic vasodilatation, rather 
than PPE, plays a key role in migraine pathophysiology.      
        Migraine has long been considered a vascular headache (Wolff, 1948; Lance, 
1993; Williamson and Hargreaves, 2001).   Dilatation of extracranial vessels during 
attacks (Drummond and Lance, 1983; Iversen, Nielsen, Olesen and Tfelt-Hansen, 
1990) may be mediated, at least in part, by release of CGRP from trigeminal nerve 
terminals as levels were found to be elevated in the external jugular vein (Goadsby, 
Edvinsson and Ekman, 1990).  In animal models of the migraine aura, focal injury or 
chemicals applied to the cerebral cortex initiate a wave of neural discharge that 
spreads slowly across the cortex, followed in its wake by depression of neural activity. 
This wave of “spreading depression” activates trigeminal nerves that innervate 
meningeal and cerebral blood vessels, leading to PPE and vasodilatation in the dura 
mater (Moskowitz, 1984). CGRP-containing sensory receptors activated by spreading 
depression in the anterior and/or posterior circulation may be responsible for the pain 
component of certain attacks (Vincent and Hadjikhani, 2007). A similar process in the 
cerebellum might account for symptoms such as dysarthria, ataxia, and dizziness 
during attacks of migraine (Vincent and Hadjikhani, 2007).  
          CGRP is a powerful dilator of cranial blood vessels (Edvinsson, Ekman, Jansen, 
McCulloch and Uddman, 1987). This may be an important source of pain in migraine, 
as Ho and colleagues (2008) found that the vasoconstrictive effect of a CGRP 
antagonist (telcagepant) was as effective as the anti-migraine drug zolmitriptan in   12 
treating migraine headache. These findings support the view that migraine headache 
may be a disorder characterized by distension of cerebral blood vessels. Additionally, 
the throbbing quality of migraine headache, the sometimes conspicuous dilatation of 
extracranial vessels, and the recognized pain sensitivity of  cranial blood vessels, 
further imply that migraine may be linked to trigeminovascular mechanisms (Lance, 
1993).   Lance proposed that an unstable trigeminovascular reflex, in conjunction with 
a fault within pain control pathways, might underlie the pathogenesis of migraine.  
        Despite the appealing logic of increased cranial blood flow resulting in migraine 
headache, vasodilatation does not necessarily equate to headache. For example, the 
headache of migraine with aura frequently begins while regional cerebral blood flow 
is diminished (Olesen, Friberg, Skyhøj Olsen, Iversen, Lassen, Andersen and Karle, 
1990). Furthermore, the presence of severe headache during the vasoconstrictive state 
that  follows  subarachnoid haemorrhage suggests  that vasodilatation is an 
‘epiphenomenon’ to nociceptive discharge rather than the cause of it (Macfarlane, 
1993). A recent study by Schoonman and co-workers (2008) has further challenged 
the view that migraine headache is necessarily associated with dilatation of cranial 
vessels.  Headache developed in 20 migraineurs several hours after intravenous 
administration of GTN.  A sensitive and non-invasive imaging technique, 3-Tesla 
magnetic resonance angiography, was used to measure blood flow in the basilar and 
internal carotid arteries and to estimate the diameter of the external carotid and major 
intracranial arteries.  No change was observed in the diameter of blood vessels or in 
basilar and internal carotid artery blood flow during attacks provoked by GTN. In 
sum, it seems reasonable to conclude that disturbances in the extracranial circulation 
may aggravate, but not necessarily initiate, the headache during attacks of migraine 
(Drummond and Lance, 1983).     13 
          Susceptibility to migraine presumably is due to an underlying innate ‘migraine 
threshold’, delicately balanced between excitation and inhibition of neural networks 
that mediate symptoms of migraine.  A pain modulation pathway that extends from 
the midbrain periaqueductal gray matter incorporates the serotonergic nucleus raphe 
magnus in the medulla and locus coeruleus in the pons (Lance and Goadsby, 2005).    
Stimulation of the locus coeruleus leads to changes in intracranial and extracranial 
blood flow and the discharge of noradrenaline from the adrenal medulla (Goadsby, 
1985), which may be a catalyst for the discharge of serotonin systemically (Lance and 
Goadsby, 2005). Together, these changes may trigger symptoms of migraine.   
       The periaqueductal grey (PAG), the locus coeruleus and the raphe nuclei are 
major components of the descending pain modulation pathways. Weiller et al. (1995) 
found that regional cerebral blood flow in the distribution of the PAG, locus coeruleus 
and raphe nuclei was greater during migraine, even after pain-relieving treatment, 
than during the headache-free interval. Although it seems likely that the PAG is 
linked to the generation of headache, more rigorous research is required to establish 
whether activation of this area is a cause or consequence of headache. It may be that 
brainstem  activation during attacks is due to trigeminal neuronal discharge 
(Moskowitz, 1993) rather than driving the increase in trigeminal nerve activity.    
2.3.  Migraine triggers 
       Stimulation of the special senses increases the intensity of headache and other 
symptoms of migraine during (Linde, 2006) and outside attacks (Kowacs, Piovesan, 
Werneck, Tatsui, Lange, Ribas and da Silva, 2001), and can also trigger attacks 
(Debney, 1984; Scharff, Turk and Marcus, 1995; Granston and Drummond, 2005).  
Conversely,  head pain increases discomfort to sensory stimulation in migraine 
sufferers (Drummond and Woodhouse, 1993; Drummond, 1997).  Even seemingly   14 
innocuous visual and auditory stimulation commonly aggravates migraine headache 
(Goadsby, 2001), consistent with the notion of an underlying disturbance of gating 
mechanisms in the brainstem.   Hypersensitivity of the special senses during migraine 
attacks may be due to loss of normal inhibitory controls, resulting in increased 
sensory discomfort and aggravation of headache (Drummond, 1997). This sensitivity 
to light and noise persists to some extent during the headache-free interval 
(Drummond, 1986; Vanagaite et al., 1997; Vingen et al., 1998). 
         Stress, a commonly recognized trigger of migraine (Passchier, 1994; Reynolds 
and Hovanitz, 2000), may also initiate or intensify attacks, perhaps by acting on  an 
unstable pain control system (Lance, 1993). In particular, stimulation from higher 
brain centres, such as the cortex or hypothalamus during stress or emotion, or 
excessive afferent input from the special senses or cranial vessels, may compromise 
the pain control system in individuals vulnerable to migraine.  Other migraine triggers 
(e.g., hormonal variations or alcohol) could also act upon the pain control system to 
increase vulnerability to attacks.   
2.4.  Hyperexcitable nociception in migraine sufferers 
        Goadsby (2001) suggested that the source of pain in migraine may be more to do 
with the “abnormal perception of the normal” than the activation of nociceptive 
pathways in the usual way that pain is generated. For example, disruption of pain 
modulating processes may contribute to photophobia and phonophobia by removing 
normal inhibitory gating mechanisms. This release of inhibitory control might also 
result in sensitization of central nociceptive pathways.  
  By-and-large, the cranial nociceptive system appears to be more excitable in 
migraine sufferers than in headache-free controls. For example, vulnerability to 
headache induced by consumption of cold foods such as ice cream is greater than   15 
usual in migraine sufferers (Raskin and Knittle, 1976; Drummond and Lance, 1984;  
Fuh et al., 2003; Selekler, Erdogan,  and Budak, 2004). Similarly, the prevalence of 
stabbing, ice pick-like pains is greater in migraine sufferers than controls, and these 
pains are likely to recur at the usual site of headache (Raskin and Schwartz, 1980; 
Drummond and Lance, 1984). Drummond and Cuomo-Granston (Drummond and 
Granston, 2003, 2004, 2005; Granston and Drummond, 2002, 2005; Cuomo-Granston, 
2008, 2009) reported that migraine sufferers were more sensitive to painful 
stimulation of the temple with ice than controls, and more readily developed 
headache. Head pain intensified photophobia in migraine sufferers but not controls 
(Drummond and Woodhouse, 1993; Drummond, 1997), an effect that might be 
relevant to the mechanism of photophobia during attacks. Temporal summation to 
painful mechanical stimulation of the supraorbital region was found to be greater in 
migraine sufferers than controls, consistent with induction of wind-up in second-order 
trigeminal nociceptive neurons (Weissman-Fogel et al., 2003). Moreover, trigeminal 
nociceptive blink reflexes were hyperexcitable in migraine sufferers during the 
headache-free interval (Sandrini et al., 2002; Katsarava et al., 2003), and 
demonstrated evidence of sensitization during attacks (Kaube et al., 2002).  
In patients with strictly unilateral migraine, pressure-pain thresholds were 
found to be lower and pericranial tenderness greater on the symptomatic than 
nonsymptomatic side during the headache-free interval, and pressure-pain thresholds 
were lower on both sides than in controls (Fernandaz-de-las-Penas et al., 2008). In 
addition, pain to palpation over the supraorbital nerve was greater on the symptomatic 
than nonsymptomatic side of the forehead in patients with strictly unilateral migraine 
(Fernandaz-de-las-Penas et al., 2009). Caputi and Firetto (1997) also detected 
mechanical hyperalgesia in the interictal period at distal emergence points of the   16 
supraorbital and greater occipital nerves of migraine sufferers. They reported that the 
frequency and intensity of migrainous attacks decreased following analgesic blockade 
of these nerves, particularly in individuals sensitive to pressure at these points.  
Together, these findings suggest that nociceptive discharge in hyperexcitable cranial 
nerves may increase susceptibility to migraine. 
Cutaneous allodynia and hyperalgesia develops in the distal extremities during 
the later stages of migraine headache (Burstein,  Cutrer, and Yarnitsky,  2000; 
Burstein, Collins and Jakubowski, 2004; Burstein and Jakubowski, 2004; Levy, 
Jakubowski and Burstein, 2004; Yarnitsky, Goor-Aryeh, Bajwa, Ransil, Cutre, Sottile 
and Burstein, 2003). The progression of hyperalgesia from the site of headache to 
more distal regions implies that sensitization spreads rostally in nociceptive networks 
as the attack progresses (Burstein et al., 2000). Moreover, pressure-pain thresholds 
were found to be lower on both sides in migraine sufferers than in controls both over 
the supraorbital nerves and over peripheral nerve trunks in the upper extremities 
during the headache-free interval (Fernandaz-de-las-Penas et al., 2009), consistent 
with persistent generalized sensitization of nociceptive networks in migraine. 
2.5.  Convergence of nociceptive input in the nucleus tractus solitarius (NTS) 
         The nucleus tractus solitarius (NTS) receives converging visceral, spinal and 
trigeminal nociceptive inputs, and is critically involved in medullary reflexes 
controlling cardiovascular, respiratory and gastrointestinal functions (Benarroch, 
2006). In a review of the literature, Boscan, Kasparov and Paton (2002) illustrated the 
potential for integration of visceral and somatic afferents within the NTS.   The 
immediate response gene c-fos plays a role in the alteration of cellular responses to 
pain signals (Hunt, Pini and Evans, 1987). Boscan et al. cited evidence that cardio-
respiratory afferent regions in the NTS receive direct projections from the spinal cord   17 
and express c-fos  immunoreactivity in response to noxious stimulation of limbs 
(spinal input), cornea (trigeminal input) and stomach (visceral input). Boscan et al. 
further studied the interaction between nociceptive and baroreceptive activity in the 
NTS of rats involving mechanical stimulation of the paw, electrical stimulation of the 
brachial nerve, and paced microinjections of GABAA  antagonist bicuculline 
methiodide, substance P, and the neurokinin 1 (NK1) receptor antagonist CP-99,994 
into the NTS. They concluded that somatic nociceptive afferents activate NK1 
receptors which, in turn, enhance the release of GABA in the NTS.  This activation 
inhibits the baroreceptor cardiac reflex and may facilitate the tachycardia and pressor 
response associated with pain. Based on their electrophysiological findings, Boscan et 
al. suggested that nociceptive inputs converge on  the NTS  via multiple afferent 
pathways.   Additionally, other brainstem and midbrain regions, such as the rostal 
ventrolateral medulla, trigeminal nuclei, parabrachial complex and the PAG, may 
relay nociceptive information to the NTS.     
          Similarly, convergence of multiple inputs to the NTS may influence autonomic 
responses, such as vomiting, to visceral stimuli.  For example, activation of vagal and 
sympathetic afferents during myocardial ischaemia evokes nausea, vomiting, 
inhibitory cardiac responses (e.g., bradycardia and hypotension) and excitatory 
cardiac responses (e.g., tachycardia and hypertension) (Longhurst, Tjen-A-Looi and 
Fu, 2001). Gastrointestinal disturbances and inhibitory cardiovascular responses are 
thought to be mediated by vagal efferents whereas excitatory cardiovascular responses 
are regulated by sympathetic efferents. During the vomiting process brainstem outputs 
include sweating and increased heart rate, a sympathetic response; increased 
salivation, a parasympathetic response; and motor responses involving contraction of 
abdominal muscles (Horn, 2008).  The association between nausea and the various   18 
responses associated with vomiting is not well understood, but it seems reasonable to 
assume  that  nausea involves communication between the brainstem centres that 
coordinate these responses and forebrain areas such as the extended amygdala (Horn, 
Ciucci and Chaudhury, 2007), which regulates responses to stress, conditioned flavor 
aversion and, possibly, anticipatory nausea and vomiting during chemotherapy.  
        Reciprocal interaction between the NTS and the trigeminal nociceptive system 
(e.g., Menetrey and Basbaum, 1987; Zerari-Mailly, Buisseret, Buisseret-Delmas, and 
Nosjean, 2005) could explain why symptoms such as headache develop during the 
motion sickness induced by optokinetic stimulation, particularly in migraine sufferers 
(Drummond and Granston, 2004, 2005; Drummond, 2002; Granston and Drummond, 
2005; Cuomo-Granston, 2008, 2009). Drummond (2002) found that nausea and 
headache were greater in migraine sufferers than controls after optokinetic 
stimulation, and scalp tenderness increased in the most nauseated subjects.  Thus, the 
disturbances responsible for nausea might also sensitize central trigeminal nociceptors 
or release inhibitory controls on their discharge.      
3.   The association between motion sickness and migraine 
        Motion sickness is associated with migraine in children (Barabas, Matthews and 
Ferrari, 1983; Jan, 1998) and adults (Cutre and Baloh, 1992; Kuritzky, Ziegler and 
Hassanein, 1981).   In fact, approximately two-thirds of migraine sufferers are prone 
to motion sickness (Baloh, 1997).  Genetic factors may underlie the tendency to 
motion sickness (Reavley, Golding, Cherkas, Spector and MacGregor, 2006; Stern, 
1996) and the neuro-otological symptoms of migraine (Baloh, 1997), but whether the 
same genes are involved in both conditions is uncertain.  
          Bijveld, Bronstein, Golding and Gresty (2008) found that subjects exposed to 
visual cues of motion while stationary developed headache more frequently than   19 
during off-vertical axis rotation.  They suggested that mechanisms responsible for 
headache during visual motion might be similar to those of migraine. In a study of 42 
migraine sufferers and 39 headache-free controls of similar age- and sex-distribution, 
a greater proportion of migraine sufferers reported that traveling in cars and buses, 
reading in the car, playing on playground equipment such as roundabouts, and 
watching wide-screen movies and movement simulators induced motion sickness 
(Drummond, 2005a). Moreover, migraine sufferers were more susceptible than 
controls to symptoms evoked by visual simulation of movement (Drummond, 2002; 
Drummond and Granston, 2004), implying that migraine is associated with abnormal 
central integration of visual and vestibular cues. 
       Females are generally more prone to motion sickness than males (Golding, 2006; 
Grunfeld and Gresty, 1998), and are especially vulnerable during menstruation 
(Golding, Kadzere and Gresty 2005).  Curiously, female predominance also applies to 
migraine (Celic, Ekuklu, Tokuc and Utku, 2005; Rasmussen, 1995; Lipton, Stewart, 
Diamond, Diamond, and Reed, 2001), and menstruation increases vulnerability to 
migraine.    Grunfeld and Gresty (1998) found an association between these female 
weighted maladies.   Female yacht crewmembers who experienced migraine reported 
greater susceptibility to motion sickness than other crewmembers.   Additionally, 
motion sickness and headache peaked during the ovulatory or menstrual phases of the 
menstrual cycle, though migraine and motion sickness did not always occur together.   
Grunfeld and Gresty commented that as symptoms common to both of these disorders 
are remarkably similar, some of the women may not have distinguished whether their 
symptoms were due to migraine or motion sickness.     
        Female sex hormones may, at least in part, predispose susceptible individuals to 
motion sickness (Golding, 2006) and migraine (Rasmussen, 1995). Hormonal   20 
influences on migraine susceptibility are under much discussion (Herzog, 2007; 
Loder, Rizzoli and Golub, 2007; MacGregor, Chia, Vohrah and Wilkinson, 1990; 
Martin, Wernke, Mandell, Ramadan, Kao, Bean, Liu, Zoma and Rebar, 2005; 
Newman, 2007; Dzoljic, Sipetic, Vlajinac, Marinkovic, Brzakovic, Pokrajac and 
Kostic, 2002; MacGregor, 1999; Martin and Behbehani, 2006a; 2006b; Silberstein 
and Merriam, 2000; Gupta, 2004; Gupta, 1994). However, sex hormones do not 
account entirely for susceptibility to motion sickness as this usually develops prior to 
puberty. Additionally, susceptibility to motion sickness gradually declines into 
adulthood, which may indicate habituation to the symptomatic effects of motion over 
time (Golding, 2006).   
        The disconcerting nature of motion sickness is a stressful experience for most 
people. Therefore, as Graaf and Gresty (1998) propose, stress responses may 
influence the neurochemistry of motion sickness and increase individual 
susceptibility.   
3.1.  Vestibular instability 
         Vertigo and dizziness are cardinal features both of migraine and motion sickness 
(Marcus, Furman and Baleban, 2005). The presence of these otoneurologic symptoms 
indicates activation of vestibular pathways.  Dizziness and vertigo often accompany 
migraine attacks (von Brevern, Zeise, Neuhauser, Clarke and Lempert, 2005; Cutrer 
and Baloh, 1992; Lance, 2000) and are frequently reported during the headache-free 
interval (Kuritzy, Ziegler and Hassanein, 1981; Lempert and Neuhauser, 2009; Cha et 
al., 2009). Indeed, around 25% of migraine sufferers experience episodes of vertigo 
(Baloh, 1997).  Collectively, these symptoms suggest that neural connections within 
vestibular pathways are compromised in migraine sufferers.   21 
        Defective calcium channel genes and subunits have been isolated in familial 
hemiplegic migraine (Baloh, 1997; Gardner, 1999, 2006; Peroutka, Wilhoit and Jones, 
1997) and in families with episodic vertigo and ataxia (Baloh, 1997). Mutations in one 
such gene (CACNA1A) lead to alterations of calcium channel activity in brain cells 
and, in turn, neurotransmission, which may explain cortical and subcortical neural 
excitability in individuals with migraine (Gardner, 2006).   Furthermore, mutations in 
CACNA1A may also depress levels of serotonin via effects on ion homeostasis and 
gene expression (Estevez, 2006).   Mutations linked to familial hemiplegic migraine 
in the genes SLC1A3 and SCN1A have also been identified (Dichgans, Freilinger, 
Eckstein, Babinin, Lorenz-Depiereuz, Biskup, Ferrari, Herzog, van den Maagdenberg, 
Pusch and Strom, 2005; Jen, Wan, Palos, Howard and Baloh, 2005). In a recent study, 
Graves and colleagues (2008) identified three new premature stop codon mutations 
specific to exon 37A in CACNA1A associated with the expression of episodic ataxia 
type 2 and, in one family, with the co-occurrence of migraine and ataxia (diagnosed 
initially as basilar migraine).  These mutations may have implications with respect to 
cerebellar function and symptoms such as vertigo.    
          Baloh (1997) proposed that an inherited mechanism, similar to that discovered 
in rare forms of migraine, may account for otoneurologic symptoms that are 
experienced in the more common varieties of migraine.   In particular, a defective 
calcium (ion) channel, primarily expressed in the brain and inner ear, could lead to 
reversible hair cell depolarization (following calcium/potassium displacement), 
resulting in the otoneurologic symptoms experienced during, and outside, attacks.      
3.2.  Gastrointestinal hypersensitivity  
        Nausea is generally described as an unpleasant wave-like sensation in the throat, 
epigastrium or abdomen that often precedes but does not always culminate in   22 
vomiting.  The physiological basis of nausea is uncertain, but may involve 
communication between  afferent pathways involved in vomiting (e.g., the 
chemoreceptor trigger zone, gastrointestinal visceral afferents and/or the labyrinth) 
(Takeda et al., 1993) and forebrain regions that integrate this sensory input with past 
experiences and concurrent sensory-motor and emotional activity (Horn et al., 2007). 
Alternatively, nausea may arise from preparatory activation of motor pathways 
involved in vomiting in the nucleus NTS and the dorsal motor nucleus of the vagus – 
the so-called “vomiting” or “emetic” centre  (Dahlof and Hargreaves, 1998; 
Mitchelson, 1992; Takedo et al., 2001). However, it is worth noting that anti-emetics 
such as the NK1 and 5-HT3 receptor antagonists suppress vomiting more effectively 
than nausea  (Sanger and Andrews, 2006), indicating only partial overlap of 
mechanisms.  
       Vagal and sympathetic afferents and vestibular inputs from the labyrinth make 
direct synaptic contact with the motor pathways involved in vomiting.  Vagal 
afferents that supply the gastrointestinal system project directly to the NTS (Lee, 
Hohman, Cai, Regalia and Helke, 2001). Vestibular inputs to the NTS were found to 
come directly from medial and inferior vestibular nuclei in the cat (Yates et al., 1994) 
and rabbit (Balaban and Beryozkin, 1994). The chemoreceptor trigger zone, located in 
the area postrema at the floor of the fourth ventricle on the upper surface of the 
medulla, detects emetic signals via circulating chemical stimuli in plasma and cerebral 
spinal fluid (Yates, Grėlot, Kermon, Balaban, Jakuš and Miller, 1994). The so-called 
“vomiting centre” may also receive indirect input via the cerebellum as 
cerebellovestibular connections project to superior, medial and inferior vestibular 
nuclei (Standring, 2005). Vomiting involves the sudden and violent expulsion of 
stomach contents, caused by powerful persistent contraction of abdominal and chest   23 
muscles.  Motor pathways involved in the coordination of vomiting originate in the 
dorsal motor nucleus of the vagus, a general efferent nucleus and the largest 
parasympathetic nucleus in the brainstem.  Approximately 80% of its neurons give 
rise to the preganglionic efferent parasympathetic fibres of the vagus nerve which, 
among other targets, supplies the muscles involved in vomiting.  
       Nausea is more common than vomiting both in migraine (Lance and Goadsby, 
2005; MacGregor, 1999) and motion sickness (Benson, 2002).  Although nausea and 
vomiting can be distressing, it is feasible that momentary relief might follow vomiting 
as it is the body’s primary mechanism to rid itself of real or suspected toxins. 
Anecdotally, this relief is sometimes associated with a reduction in headache during 
attacks of migraine (Horton, 2010), perhaps through reciprocal  communication 
between the NTS and trigeminal nucleus caudalis.   
       Nausea is associated with visceral pain following intra-abdominal operations 
(Andrews, 1992; Mitchelson, 1992) and with irradiation of the abdomen (Gerstner, 
1960), possibly because afferent pathways to the NTS and reticular formation are 
activated following the handling of viscera during operative procedures or because of 
tissue damage to viscera following radiation therapy (Blair, 1985; Barber and Yuan, 
1989).  Additionally, head irradiation may raise intracranial pressure due to local 
oedema and inflammation, which then appears to stimulate nausea and vomiting.  
Kowalski and colleagues (2006) pointed out that studies investigating nausea 
generally have focused on mechanisms leading to the subjective experience rather 
than on neurophysiological activity.   In particular, there is a dearth of research with 
respect to functional imaging of brain activity during nausea and vomiting. As the 
brain’s emetic response is inadequately delineated, cortical imaging techniques such 
as functional magnetic resonance imaging (fMRI) may provide insights into the neural   24 
mechanisms and time course of the emetic experience.  fMRI may indeed provide 
useful  physiological correlates in much the same way as positron emission 
tomography has clarified dose-response relationships in the development of 
pharmacological treatments targeting substance P-NK1 receptors in the NTS and area 
postrema in the control of the vomiting reflex in animals and chemotherapy induced 
nausea and vomiting in humans (Hargreaves, 2006).    
  Eighty-two percent of children identified as having cyclic vomiting syndrome 
manifest symptoms typical of migraine.  Interestingly, in children susceptible to 
migraine-associated cyclic vomiting, motion sickness was more likely to trigger 
vomiting and other migrainous symptoms than in children with non-migraine cyclic 
vomiting - 10% versus 0% (Li, Murray, Heitlinger, Robbins and Hayes, 1999).   In 
longitudinal studies, children with a history of recurrent vomiting of unknown cause 
were found to be at increased risk of migraine in adulthood (Jan, 1998; Jan, Camfield, 
Gordon and Camfield, 1997). Furthermore, children with a history of motion sickness, 
migraine, or family history of migraine were more likely to vomit after mild head 
injury (Jan et al., 1997). The overlap between vomiting, migraine and motion sickness 
seen in childhood suggests that the gastrointestinal system is hyper-excitable in 
vulnerable individuals from an early age.   
       Abdominal migraine is associated with nausea and vomiting and typically recurs 
in infancy, childhood, and adolescence (Headache Classification Subcommittee of the 
International Headache Society, 2004), then apparently evolves into more typical 
migraine during puberty and early adulthood (Blau and MacGregor, 1995; d’Onofrio, 
Cologno, Buzzi, Petretta, Caltagirone, Casucci and Bussone, 2006).  Recently, 
d’Onofrio et al. (2006) described a rare case of a woman who fulfilled the diagnostic 
criteria for late onset abdominal migraine.  Abdominal pain attacks began in her   25 
adolescence and persisted until age 21.  Thereafter she experienced migraine 
headache accompanied by nausea, photophobia and phonophobia.   However, the 
transition from childhood abdominal migraine to adult migraine has been challenged 
by Blau and MacGregor (1995), who claimed that the majority of migraine sufferers 
do not experience abdominal discomfort during migraine attacks. Despite these 
contrary views, the link between gastrointestinal disturbance and  head pain in 
migraine is certainly well documented (Blau, 1993; Botney, 1981; Olesen, 1978; 
Rasmussen, Jensen and Olesen, 1991).  
        Nausea and vomiting may develop in migraine headache because of close 
functional interconnections between the trigeminovascular system and the NTS 
(Knight, 2005).   Drummond and Cuomo-Granston (Drummond and Granston, 2004, 
2005; Granston and Drummond, 2002; Cuomo-Granston, 2008, 2009) observed that 
migraine sufferers developed nausea in the presence of head pain whereas controls 
remained asymptomatic.  Migraine sufferers initially developed headache following 
painful stimulation of the temple, and nausea developed gradually as the procedure 
progressed. Optokinetic stimulation enhanced the incremental upsurge of nausea 
evoked by head pain, presumably because motion sickness increased the excitability 
of emetic or trigeminal nociceptive circuits (Drummond and Granston, 2005).   A 
similar synergistic relationship between nausea and headache could develop during 
attacks of migraine.  Since serotonin (5-HT) specific anti-migraine compounds 
alleviate nausea and headache, this may indicate an action via 5-HT1B/1D receptors in 
the NTS. Indeed, the 5-HT1B/1D receptor agonists eletriptan and naratriptan were found 
to inhibit activity  in NTS neurons that responded to electrical stimulation of the 
superior sagittal sinus, a major vein of the dura mater (Hoskin, Lambert, Donaldson, 
and Zagami, 2004). Thus, serotonergic agonists might not only modulate nociceptive   26 
activity in the trigeminovascular system but also directly suppress the firing rate of 
NTS neurons that mediate gastrointestinal disturbances.  
4.   Overlapping mechanisms in migraine and motion sickness 
4.1. Gastrointestinal symptoms 
       Although peripheral pathways mediate the actual vomiting process (Lang, 1999; 
McMillin, Richards, Mein and Nelson, 1999), nausea and vomiting in migraine 
(Dahlof and Hargreaves, 1998) and motion sickness (Takeda et al., 2001; Cass, 
Ankerstjerne, Yetiser, Furman, Balaban, and Aydogan, 1997) are assumed to originate 
within the central nervous system.   In support of the central generation of nausea in 
motion sickness, Levine, Chillas, Stern and Knox (2000) found that while gastric 
tachyarrythmia resolved following administration of 5-HT receptor antagonist 
antiemetics during optokinetic stimulation, nausea (and other symptoms of motion 
sickness) still developed.       
       A hypersensitive ‘emetic centre’ (reflected by a low threshold for the emetic 
response) may underlie susceptibility to motion sickness (Takedo et al., 2001).  As the 
same central mechanisms orchestrate emesis, regardless of the triggering condition, 
and migraine sufferers are prone to motion sickness, ‘emetic centre’ hypersensitivity 
could also explain the recruitment of nausea in attacks of migraine. Once established, 
nausea and headache could escalate in a positive loop. 
4.2. Vestibular symptoms 
       Dizziness or vertigo is frequently reported in the headache-free interval as well as 
during attacks of migraine (Marano, Marcelli, Di Stasio, Bonuso, Vacca, Manganelli, 
Marciano and Perretti, 2005; Baloh, 1997; Cutrer and Baloh, 1992), often in 
association with nausea (Baloh, Foster, Yue and Nelson, 1996; Harris, 1999).  The 
link between headache and dizziness/vertigo may reflect  a functional  interaction   27 
between the trigeminal and vestibular systems.   Lesions associated with vestibular 
structures commonly produce nystagmus.  Marano et al. (2005) reported that 
spontaneous nystagmus developed more readily in migraine sufferers than in controls 
following unilateral electrical stimulation of the supraorbital region of the forehead, 
suggesting that trigeminal nerve activity evoked vestibular dysfunction in 
migraineurs.   
  In the case of motion sickness, impulses are relayed from the vestibular nuclei 
to the cerebellum, and then to the NTS  (Mitchelson, 1992).    Although motion 
sickness develops readily in most migraine sufferers, motion sickness is not co-
morbid with common peripheral vestibular disorders such as Meniere’s disease, 
benign paroxysmal positional vertigo or vestibular neuritis (Marcus et al., 2005).  
Thus, the reciprocal relationship between motion sickness and migraine is consistent 
with the notion that central rather than peripheral  pathways involved in their 
generation are shared. These pathways may include: 
•  Projections from the trigeminal nucleus caudalis to the vestibular nuclei 
(Diagne, Valla, Delfini, Buisseret-Delmas and Buisseret, 2006). 
•  Indirect influences on the vestibular nuclei, mediated by trigeminovascular 
reflexes that regulate blood flow through the cerebellar and vertebrobasilar 
vasculature (Vincent and Hadjikhani, 2007).   
•  Projections from the trigeminal nucleus caudalis and vestibular nuclei to the 
NTS which, in turn, project to autonomic output pathways (Menėtrey  and 
Basbaum, 1987). 
•  Rostral projections from the trigeminal nucleus caudalis, vestibular nuclei and 
NTS to the hypothalamus, thalamus, limbic system and cerebral cortex (Marcus 
et al., 2005; Menėtrey and Basbaum, 1987), and top-down influences from these   28 
higher brain centres on brainstem processing. The net sum of this central 
integration may influence the expression and intensity of symptoms such as 
dizziness, nausea and headache. 
 4.3. Vascular disturbances  
        Vasodilatation of cranial vessels (both extra-  and intracranial) has long been 
regarded as important in the pathophysiology of migraine (Wolff, 1948; Wolff, 1972; 
Botney, 1981; Moskowitz, 1993; Drummond and Lance, 1983; Lance, 1993; Lance 
and Goadsby, 2005).  As noted in Section 2.2, vasodilatation during attacks of 
migraine may be driven in a vicious circle by an interaction between nociceptive 
trigeminal-parasympathetic vasodilatation (Lance et al., 1983) and painful neurogenic 
inflammation (Moskowitz, 1993; Buzzi and Moskowitz, 2005). Extracranial blood 
vessels dilate more readily in migraine sufferers than controls during psychological 
stress (Drummond, 1982), head pain (Drummond, 1997; Drummond and Granston, 
2005) and optokinetic stimulation (Drummond and Granston, 2004; Cuomo-Granston, 
2008, 2009). This heightened responsiveness could amplify the vascular component 
of migraine. 
        Neurogenic inflammation involves a surge of vasoactive neurotransmitters 
(substance P, neurokinin A, calcitonin gene-related peptide) that provoke 
vasodilatation and possibly the prolonged pain associated with a migraine attack 
(Moskowitz, 1993). In this regard, Buzzi, Bonamini and Moskowitz (1995) suggested 
that headache may be considered a consequence of threatened injury to the brain. 
Similarly, Edvinsson and Uddman (2005) suggested that the trigeminovascular 
vasodilator reflex is, in part, generated via CGRP and VIP to offset cerebrovascular 
constriction.    29 
        Motion sickness is commonly associated with facial pallor and cold sweating 
(Marcus et al., 2005), but may also be associated with increases in skin oxygen and 
flushing (Harm, Beatty and Reschke, 1987).  In a study involving eccentric vertical 
axis rotation, facial vasodilatation peaked at the commencement of rotation (during 
vestibular stimulation), even before the onset of motion sickness (Kolev, Möller, 
Nilsson and Tibbling, 1997).  Together, these findings suggest that blood is diverted 
away from facial capillaries to deeper blood vessels as nausea develops (Marcus et al., 
2005). A similar process may account for facial pallor in migraine.  In a series of 
experiments by Golding (1992), phasic skin conductance responses increased 
progressively in the forehead during provocative motion procedures  (reflecting 
prodromal sweating in nauseated subjects), and decreased in line with subjective 
recovery as motion sickness resolved. Golding pointed out that the combination of 
sweating with pallor in motion sickness is an anomaly, as thermoregulatory sweating 
is generally associated with peripheral vasodilatation. He suggested that the 
thermoregulatory value of cold sweating in motion sickness might be as a preparatory 
response to cool the body in anticipation of impending muscular activity.  However, 
the physiological benefit of this response with regard to motion sickness is unclear.   
       Drummond and Cuomo-Granston (Drummond and Granston, 2004; Cuomo-
Granston, 2008, 2009) investigated the association between changes in facial blood 
flow and symptoms of motion sickness evoked by optokinetic stimulation. Their 
research involved one central experiment that consisted of six experimental 
conditions. On separate occasions migraine sufferers and healthy controls were 
exposed to optokinetic stimulation with or without painful stimulation of the head or 
limb (Figure 1). During optokinetic stimulation, subjects sat on a stationary chair and 
watched vertical black and white stripes moving past. This created visual illusions and   30 
a sense of movement: the stripes appeared to take on a 3-dimensional aspect, move 
further away and grow wider, and to slow down or stop altogether whereas the chair 
that the subject sat on seemed to spin. The motion sickness evoked by this illusion of 
movement is associated with nausea, headache and other symptoms of migraine, 
which are generally more intense in migraine sufferers than controls (Drummond, 
2002). Headache developed in migraine sufferers but not controls during optokinetic 
stimulation, and extracranial vasodilatation was greater in migraine sufferers than 
controls (Drummond and Granston, 2004). Although the headache intensified when 
ice was applied to the temple during optokinetic stimulation, there seemed to be no 
direct correspondence between vasodilatation and headache intensity as the ice did not 
provoke additional increases in facial blood flow.  
The periaqueductal grey (PAG) is involved in pain control and autonomic 
regulation of the stress response (Behbehani, 1995).  Carrive and Bandler (1991) 
detected extracranial vasodilatation when D.L. homocysteic acid was administered 
into a restricted portion of the lateral pretentorial PAG in unanesthetized and 
paralyzed decerebrate cats, a site that evokes a threat display (hisses, howls, retraction 
of the corners of the mouth and ears) in freely moving cats  as part of a defense 
response.   Thus, the extracranial vasodilatation observed by Drummond and Cuomo-
Granston (Drummond and Granston, 2004; Cuomo-Granston, 2008, 2009) in migraine 
sufferers during optokinetic stimulation may have reflected a defense response 
involving the PAG. In support of this view, anticipation of head pain also evoked an 
exaggerated extracranial vasodilator response in migraine sufferers (Drummond and 
Granston, 2005). Increases in sympathetic activity provoked by activation of  the 
defense response may also account for cold sweating during motion sickness.   31 
5.   Serotonin, migraine and motion sickness 
        Pharmacological studies indicate that serotonin (5-HT) may be involved both in 
migraine and motion sickness.  In experiments on cats, 5-HT inhibited  the 
transmission of neural impulses in the lateral vestibular nuclei (Kishimoto, Sasa and 
Takaori, 1991, 1994).  Triptans may evoke analgesic anti-migraine activity in the 
trigeminal nucleus caudalis, and anti-emetic effects in the NTS, by acting on the 
numerous 5-HT1  receptor sites in these locations  (Pascual,  del Arco, Romon, del 
Omo, Castro and Pazos, 1996;  Hoskin et al., 2004). Serotonin prevents motion-
induced emesis in animals (Javid and Naylor, 2006; Okada, Saito and Matsuki, 1996), 
and 5-HT1A agonists inhibit vomiting during motion sickness in cats (Lucot, 1989; 
Yates, Miller and Lucot, 1998) and the Asian musk shrew (Okada, Torii, Saito and 
Matsuki, 1994).  However, findings in animal research do not necessarily extrapolate 
to clinical efficacy in humans (Reid, Sciberras, Gertz, Reinhardt, Lui, Golding and 
Stott, 1998; Hasler, 1999; Peroutka, 2005). For example, the NK1 receptor antagonist 
L-758,298 was found to have motion-related anti-emetic properties in animals (Reid, 
Palmer, Wright, Clemes, Troakes, Somal, House and Stott, 2000), but proved 
ineffective in preventing motion-induced nausea in humans (Reid et al., 1998).  By 
necessity, the benchmarks used to determine motion sickness in animals are 
constrained to vomiting or the consumption of non-nutritive substances such as kaolin 
(clay), an illness response seen in rats considered comparable to vomiting (Okada et 
al., 1996; Takeda, Morita, Hasegawa, Horii, Kubo and Matsunaga, 1993).  The 
absence of an animal analogue of nausea limits the degree to which findings from 
animal research can be translated to humans. 
        In a pilot study by Marcus and Furman (2006),  five migraine sufferers with 
migrainous vertigo and another five without vestibular symptoms were pretreated   32 
with either the 5-HT1B/D receptor agonist rizatriptan or placebo before vertical axis 
rotation tests.  Rizatriptan inhibited symptoms of motion sickness in migraineurs 
susceptible to vestibular symptoms during migraine attacks, but not in migraineurs 
without vestibular symptoms.  Whilst these preliminary findings suggest a potential 
link between serotonin and motion sickness  in migraine sufferers, they require 
confirmation in studies using larger numbers of patients with and without a history of 
migraine.  Baloh (1997) pointed out that anti-migraine treatments such as ergotamine 
and sumatriptan are probably of little help for the treatment of migraine-associated 
vertigo, although he did report that several patients found sumatriptan, if taken early, 
aborted vertigo (Evans and Baloh, 2001).  Consistent with this observation, 
zolmitriptan was found to alleviate migrainous vertigo in a small group of sufferers 
(Neuhauser, Radtke, Breven and Lempert, 2003).   
        In studies in our laboratory (Drummond, 2005b, 2006), levels of 5-HT within the 
central nervous system apparently influenced the development of symptoms of 
migraine and motion sickness.  Drummond investigated symptoms of motion sickness 
(Drummond, 2005b) and sensitivity to light (Drummond, 2006) in migraine sufferers 
and healthy controls following consumption of an amino acid drink without the 
serotonin precursor L-tryptophan, to transiently reduce brain serotonin synthesis. In 
the comparison condition, participants consumed an amino acid drink that included L-
tryptophan. Drummond (2005b) found that dizziness, nausea and visual illusions were 
enhanced in tryptophan-depleted healthy controls during exposure to optokinetic 
stimulation, to levels comparable to those reported by migraine sufferers.  These 
findings suggest that depleted brain serotonin activity may be involved in vestibulo-
ocular disturbances during motion sickness, and that a serotonergic deficit might 
increase vulnerability to symptoms of migraine. Tryptophan-depleted migraine   33 
sufferers and controls were more sensitive to light, reporting greater glare and light-
induced pain than in others without tryptophan depletion (Drummond, 2006).  In 
addition, headache worsened in tryptophan-depleted migraine sufferers, and nausea 
intensified both in migraine sufferers and controls in the presence of residual motion 
sickness following exposure to optokinetic stimulation.  These findings are consistent 
with the notion that reduced brain 5-HT synthesis augments migrainous symptoms 
(Drummond, 2006). 
          Serotonergic activity has been linked to migraine during (Hasler, 1999; 
Ladabaum and Hasler, 1999; Silberstein, 1994) and outside attacks (Afra, Proietti 
Cecchini, Sandor and Schoenen, 2000).  However, the precise role of 5-HT is not 
clear (Evers, Quibeldey, Grotemeyer, Suhr and Husstedt, 1999; Ferrari and Saxena, 
1993; Fontes Ribeiro, Cotrim, Morgadinho, Ramos, Seabra Santos and Macedo, 
1990).   During a migraine attack the trigeminal sensory system presumably activates 
second-order nociceptive neurons within the brainstem, which relay signals to 
autonomic brainstem nuclei and higher cortical pain processing centres. In turn, these 
afferent impulses initiate head pain and serial or parallel activation of sensory and 
efferent autonomic pathways that trigger nausea and gastrointestinal disturbances 
(Dahlof and Hargreaves, 1998).  Silberstein (1994) proposed that 5-HT modulates 
rather than mediates sensory responsiveness by acting on serotonergic receptors 
distributed widely throughout the brain (Millan, 2002).  Serotonergic neurons 
originating in the raphe nuclei of the brain stem have extensive projections to the 
cortex, hippocampus, basal ganglia, thalamus, cerebellum, and spinal cord.  These 
neurons play a role in controlling levels of arousal and sleep.  In addition they 
modulate sensory input, particularly for pain (Millan, 2002), and could thus influence 
susceptibility to migraine.      34 
6.   Summary and conclusions 
Characteristics of the migraine predisposition include: 
•  susceptibility to vestibular symptoms and motion sickness 
•  susceptibility to nausea, headache and photophobia induced by facial pain 
•  persistence of cranial hyperalgesia (scalp and cranial nerve tenderness, ice 
cream headache, ice pick pain), exaggerated trigeminal-nociceptive reflexes, 
and possibly hyperalgesia in the distal extremities, between episodes of 
headache 
•  persistence of photophobia and phonophobia between headache episodes 
•  an exaggerated response in extracranial blood vessels to stressful stimuli 
Together, these characteristics suggest that migrainous mechanisms persist 
subclinically during the headache-free interval. Whether this simply represents 
residual activity from previous episodes or whether this subclinical activity increases 
susceptibility to further attacks of migraine has not been resolved. However, the 
expected daily incidence of migrainous attacks increased from 8% to 44% following 
painful stimulation of the temple during and after optokinetic stimulation (Granston 
and Drummond, 2005), consistent with the view that heightened activity in pathways 
responsible for migrainous symptoms increases susceptibility to attacks.   
       The mechanisms that underlie susceptibility to recurrent attacks of migraine may 
also increase vulnerability to motion sickness in migraine sufferers.  As illustrated in 
Figure 2, this might include:    
•  Disruption of brainstem mechanisms that normally inhibit sensory discomfort to 
light, noise and head pain. This results in the sensitization of trigeminal 
nociceptive neurons and their rostral projections, and neurons in the NTS that 
mediate nausea and vomiting.    35 
•  Sensory stimulation that intensifies activity in, and sensitization of, these neural 
circuits. 
•  Trigeminovascular reflexes and neurogenic inflammation that  develop in 
response to, then aggravate,  the brainstem disturbances responsible for 
symptoms of migraine. This establishes a vicious circle akin to a neural “wind-
up” phenomenon.   
       Whether the vascular and neurochemical cascade of migraine is evoked by 
spontaneous discharge of a cyclical brainstem disturbance,  or originates in the 
periphery, is uncertain.  However, as a reduction in brain synthesis of 5-HT intensifies 
dizziness, nausea, photophobia and headache (Drummond 2005b; Drummond, 2006), 
a central serotonergic disturbance  that increases the excitability of the trigeminal 
nucleus caudalis, NTS and vestibular nuclei may explain the link between motion 
sickness and migraine. 
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Figure legends 
 
Figure 1.   Experimental conditions and sessions.   Bullets indicate the 3 sessions 
participants attended.  Each session involved two conditions (A and B).  The order of 
sessions varied between participants.   The interval between each session was 
approximately one month. 
Figure 2.  Mechanisms that may contribute to symptoms of motion sickness and 
migraine. The key structures in the brainstem that mediate these symptoms include the 
trigeminal nucleus caudalis, the vestibular nuclei and the nucleus tractus solitarius. 
Arrows represent activation, whereas the flat terminal linked with pain modulation 
processes represents inhibition. Disruption of these inhibitory pain modulation 
processes may increase sensitivity to light, noise and head and/or neck pain, provoke 
symptoms of migraine and, ultimately, sensitize key brainstem nuclei. Once initiated, 
the trigeminovascular system could amplify trigeminal nociceptive sensations through 
a vicious circle involving neurogenic inflammation and extracranial vasodilatation. 
Reciprocal interactions between the trigeminal nucleus caudalis and the nucleus 
tractus solitarius may then result in escalation of nausea and headache. In addition, 
links between the trigeminal nucleus caudalis and the vestibular nuclei might mediate 
vestibular disturbances. Persistent excitability of these brainstem nuclei could increase 
vulnerability to symptoms both of motion sickness and migraine.  59 
Session                   Condition (A)                                                                                       Condition (B)                     
 
                                                                                             followed by 
•      optokinetic stimulation alone                                                                 Ice on temple after optokinetic stimulation 
 
                                                                                            followed by 
•      Ice on temple before optokinetic stimulation                                         Ice on temple during optokinetic stimulation 
 
                                                                                                         followed by  
•     Hand in ice-water before optokinetic stimulation                                 Hand in ice-water during optokinetic stimulation 
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